Plasma antioxidants, genetic variation in SOD2, CAT, GPX1, GPX4, and prostate cancer survival

Affiliations

¹ Authors' Affiliations: Departments of Epidemiology and Biostatistics, Urology, University of California, San Francisco, California; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Departments of Epidemiology, and Nutrition, Harvard School of Public Health, Boston, Massachusetts; and Department of Food Science and Human Nutrition, University of Illinois, Urbana, Illinois erin.vanblarigan@ucsf.edu.
² Authors' Affiliations: Departments of Epidemiology and Biostatistics, Urology, University of California, San Francisco, California; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Departments of Epidemiology, and Nutrition, Harvard School of Public Health, Boston, Massachusetts; and Department of Food Science and Human Nutrition, University of Illinois, Urbana, IllinoisAuthors' Affiliations: Departments of Epidemiology and Biostatistics, Urology, University of California, San Francisco, California; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Departments of Epidemiology, and Nutrition, Harvard School of Public Health, Boston, Massachusetts; and Department of Food Science and Human Nutrition, University of Illinois, Urbana, Illinois.
³ Authors' Affiliations: Departments of Epidemiology and Biostatistics, Urology, University of California, San Francisco, California; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Departments of Epidemiology, and Nutrition, Harvard School of Public Health, Boston, Massachusetts; and Department of Food Science and Human Nutrition, University of Illinois, Urbana, Illinois.
⁴ Authors' Affiliations: Departments of Epidemiology and Biostatistics, Urology, University of California, San Francisco, California; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Departments of Epidemiology, and Nutrition, Harvard School of Public Health, Boston, Massachusetts; and Department of Food Science and Human Nutrition, University of Illinois, Urbana, IllinoisAuthors' Affiliations: Departments of Epidemiology and Biostatistics, Urology, University of California, San Francisco, California; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Departments of Epidemiology, and Nutrition, Harvard School of Public Health, Boston, Massachusetts; and Department of Food Science and Human Nutrition, University of Illinois, Urbana, IllinoisAuthors' Affiliations: Departments of Epidemiology and Biostatistics, Urology, University of California, San Francisco, California; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Departments of Epidemiology, and Nutrition, Harvard School of Public Health, Boston, Massachusetts; and Department of Food Science and Human Nutrition, University of Illinois, Urbana, Illinois.

PMID: 24711484
PMCID: PMC4047147
DOI: 10.1158/1055-9965.EPI-13-0670

Plasma antioxidants, genetic variation in SOD2, CAT, GPX1, GPX4, and prostate cancer survival

Erin L Van Blarigan et al. Cancer Epidemiol Biomarkers Prev. 2014 Jun.

. 2014 Jun;23(6):1037-46.

doi: 10.1158/1055-9965.EPI-13-0670. Epub 2014 Apr 7.

Affiliations

¹ Authors' Affiliations: Departments of Epidemiology and Biostatistics, Urology, University of California, San Francisco, California; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Departments of Epidemiology, and Nutrition, Harvard School of Public Health, Boston, Massachusetts; and Department of Food Science and Human Nutrition, University of Illinois, Urbana, Illinois erin.vanblarigan@ucsf.edu.
² Authors' Affiliations: Departments of Epidemiology and Biostatistics, Urology, University of California, San Francisco, California; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Departments of Epidemiology, and Nutrition, Harvard School of Public Health, Boston, Massachusetts; and Department of Food Science and Human Nutrition, University of Illinois, Urbana, IllinoisAuthors' Affiliations: Departments of Epidemiology and Biostatistics, Urology, University of California, San Francisco, California; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Departments of Epidemiology, and Nutrition, Harvard School of Public Health, Boston, Massachusetts; and Department of Food Science and Human Nutrition, University of Illinois, Urbana, Illinois.
³ Authors' Affiliations: Departments of Epidemiology and Biostatistics, Urology, University of California, San Francisco, California; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Departments of Epidemiology, and Nutrition, Harvard School of Public Health, Boston, Massachusetts; and Department of Food Science and Human Nutrition, University of Illinois, Urbana, Illinois.
⁴ Authors' Affiliations: Departments of Epidemiology and Biostatistics, Urology, University of California, San Francisco, California; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Departments of Epidemiology, and Nutrition, Harvard School of Public Health, Boston, Massachusetts; and Department of Food Science and Human Nutrition, University of Illinois, Urbana, IllinoisAuthors' Affiliations: Departments of Epidemiology and Biostatistics, Urology, University of California, San Francisco, California; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Departments of Epidemiology, and Nutrition, Harvard School of Public Health, Boston, Massachusetts; and Department of Food Science and Human Nutrition, University of Illinois, Urbana, IllinoisAuthors' Affiliations: Departments of Epidemiology and Biostatistics, Urology, University of California, San Francisco, California; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Departments of Epidemiology, and Nutrition, Harvard School of Public Health, Boston, Massachusetts; and Department of Food Science and Human Nutrition, University of Illinois, Urbana, Illinois.

PMID: 24711484
PMCID: PMC4047147
DOI: 10.1158/1055-9965.EPI-13-0670

Abstract

Background: Antioxidants may reduce risk of aggressive prostate cancer, and single-nucleotide polymorphisms (SNP) in antioxidant genes may modify this association.

Methods: We used Cox proportional hazards regression to examine circulating prediagnostic α-tocopherol, γ-tocopherol, and lycopene; SNPs in SOD2 (n = 5), CAT (n = 6), GPX1 (n = 2), GPX4, (n = 3); and their interactions and risk of lethal prostate cancer among 2,439 men with nonmetastatic prostate cancer in the Health Professionals Follow-up Study and Physicians' Health Study.

Results: We observed 223 events over a median follow-up of 10 years. Higher α-tocopherol levels were associated with lower risk of lethal prostate cancer [HR 3rd versus 1st quartile (Q): 0.51; 95% confidence interval (CI), 0.30-0.89; HR 4th versus 1st Q: 0.68; 95% CI, 0.41-1.13; P trend: 0.02]. Men homozygous for the less common allele (G) at rs3746165 in GPX4 had a 35% lower risk of lethal prostate cancer compared with men homozygous for the more common allele (A; HR, 0.65; 95% CI, 0.43-0.99). Among men homozygous for the less common allele in rs3746165, high γ-tocopherol levels were associated with a 3.5-fold increased risk of lethal prostate cancer (95% CI, 1.27-9.72; P value, 0.02; interaction P value, 0.01).

Conclusions: Among men with nonmetastatic prostate cancer, higher circulating prediagnostic α-tocopherol may be associated with lower risk of developing lethal disease. Variants in GPX4 may be associated with risk of lethal prostate cancer, and may modify the relation between γ-tocopherol and prostate cancer survival.

PubMed Disclaimer

References

1. Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, et al. Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr. 2007;86:672–81. - PubMed
1. Giovannucci E. Tomato products, lycopene, and prostate cancer: a review of the epidemiological literature. J Nutr. 2005;135:2030S–1S. - PubMed
1. Chan JM, Gann PH, Giovannucci EL. Role of diet in prostate cancer development and progression. J Clin Oncol. 2005;23:8152–60. - PubMed
1. Albanes D, Heinonen OP, Huttunen JK, Taylor PR, Virtamo J, Edwards BK, et al. Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study. Am J Clin Nutr. 1995;62:1427S–30S. - PubMed
1. Gann PH, Ma J, Giovannucci E, Willett W, Sacks FM, Hennekens CH, et al. Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res. 1999;59:1225–30. - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Plasma antioxidants, genetic variation in SOD2, CAT, GPX1, GPX4, and prostate cancer survival

Affiliations

Plasma antioxidants, genetic variation in SOD2, CAT, GPX1, GPX4, and prostate cancer survival

Authors

Affiliations

Abstract

References

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous